This 2015 phase II, double-blind, randomized controlled trial assessed the efficacy and safety of beloranib, a methionine aminopeptidase 2 (MetAP2) inhibitor, in 147 obese adults over 12 weeks. Participants received subcutaneous beloranib at doses of 0.6, 1.2, or 2.4 mg, or placebo, without dietary or exercise interventions. Beloranib induced dose-dependent
